 HTG Molecular Diagnostics, Inc. HTGM HTG, a life science company whose mission is to advance precision medicine, today announced its HTG EdgeSeq technology was highlighted in several posters presented at the American Society of Clinical Oncology ASCO 2020 Virtual program. We are thrilled to see our technology highlighted in so many abstracts at this years ASCO conference, said Byron Lawson, Senior Vice President and Chief Commercial Officer. It is very satisfying to see our partners and customers enhancing their research and findings with our HTG EdgeSeq technology, and we look forward to building upon this momentum. 